In addition, the ability of the bioadhesive polymer to produce a persistent mucosal barrier effect was also demonstrated after a brief washing of the esophageal mucosa with saline after perfusion with Esoxx. Gastroesophageal reflux, or acid reflux, occurs when the acid produced naturally by the stomach spreads from the stomach to the esophagus. Gastroesophageal reflux can be caused by hyperacidity or a drastic change in eating habits. Gastroesophageal reflux disease (GERD) causes heartburn.

Swallow 1 sachet of 10 ml after the main meals and before bedtime, or as recommended by the doctor.

Our advice from pharmacy experts

Esoxx One x 14 sachets - Relief for Heartburn, Epigastric Pain, Reflux of Gastric, Epigastric Pain Description: Thanks to its original and innovative formula, it acts mechanically, exerting a protective mucoadhesive action, and promoting healing. It thus provides rapid relief from pain. A NEW THERAPEUTIC APPROACH Esoxx One is characterised by its protective mucoadhesive effect, prolonging the action of the active substances and promoting healing. It provides rapid and effective relief from the pain of gastroesophageal reflux disease. DOSAGE AND PRECAUTIONS FOR USE OF ESOXX ONE The results showed that Esoxx perfused at 1 mL/minute for 10 minutes, after mucosal damage induction, preventing the penetration of the EB dye in the mucosa and acting as a topical mucosal barrier. Chondroitin is a fundamental component of the esophageal mucosa. It has an anti-inflammatory effect by stimulating the growth of fibroblasts. It also plays an important role in cell protection by reducing the proteolytic activity of pepsin. Thus, it relieves and prevents tissue damage

We found that the most severe lesions, characterized by erosions involving more than 50% of mucosal area and extending through more than 50% of the epithelial stratified layer, were observed in all the specimens perfused with acid solution for 90 minutes or with acid plus pepsin for 60 minutes. We considered this a suitable and reproducible model to induce a chemical lesion of esophageal mucosa.Esoxx ® (Alfa Wassermann, Bologna, Italy) is a new medical device for the topical treatment of the symptoms of gastroesophageal reflux disease (GERD). The product is based on a mixture of hyaluronic acid (HA) and chondroitin sulfate (CS) in a bioadhesive carrier Lutrol ® F 127 (poloxamer 407) (BASF, Milan, Italy), which acts as a buffering agent to form a barrier and to prolong the action on esophageal mucosa. 1 Hyaluronic acid, an essential component of epithelia, is a pivotal molecule in the healing process and plays an important role in lubrication, cell differentiation and cell growth